...if only it was printed....
"the dmd market is underserved and estimated to grow by a value of 10 billion dollars by 2023".....
..."the global anti inflammatory market is estimated to be over 190 billion by 2027 and Antisense is well positioned to capitalise upon its success to date with ATL1102"
is that their answer; sell dmd 2023 sell anti inflam 2027? With a bunch of pipeline indications from 2021+
Ann: ANP and MCRI new R&D collaboration for ATL1102, page-266
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |